- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 27, Issue 37, 2021
Current Pharmaceutical Design - Volume 27, Issue 37, 2021
Volume 27, Issue 37, 2021
-
-
The State of the Problem of Achieving Extremely Low LDL Levels
Authors: Victoria Korneva, Tatiana Kuznetsova and Ulrich JuliusPatients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At Read More
-
-
-
MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges
Authors: Sara E.L. Tolouei, Tatiana Z. Curi, Lislaine M. Klider and Arquimedes G. JuniorCardiovascular diseases (CVDs) are a group of non-communicable disorders of the heart and blood vessels. Although lifestyle changes as well as pharmacological treatments and surgical interventions are available in many countries, CVDs are still considered the number one cause of mortality worldwide. Hence, considering that most CVDs are caused by genetic and environmental imbalances, micro-RNAs (miRNAs or Read More
-
-
-
CA125: An Increasingly Promising Biomarker of Heart Failure
Authors: Chunqi Pan, Mengyun Zhou, Ying Jian, Yuanyuan Zeng, Mingwei Wang and Feng ChenCA125 is a well-known tumor marker for diagnosis, monitoring, and risk stratification in ovarian cancer. It is not specific for malignant tumors and may be elevated in benign disease. In the past two decades, increasing evidence has emerged suggesting that the plasma level of CA125 can serve as a novel surrogate of heart failure (HF). CA125 in patients with HF is synthesized by serous epithelial cells in response to both mechani Read More
-
-
-
Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Authors: Ashif Iqubal, Aamir Khan, Adeeba laeeq, Kabil Malhotra, Mohd. A. Ansari and Syed E. HaqueCardiovascular disease (CVD) is a complex disease with multifactorial origin where cardiac membrane damage, inflammation, persistent oxidative stress, apoptosis and mitochondrial damage play a significant role. CVD is associated with high mortality rate and poor clinical outcome due to late diagnosis. Therefore, reliable accurate and specific biomarkers help in timely diagnosis and prevention of further damage. Beside creati Read More
-
-
-
Red Cell Distribution Width: A Routinely Available Biomarker with Important Clinical Implications in Patients with Atrial Fibrillation
Authors: Anna C. Valenti, Marco Vitolo, Jacopo F. Imberti, Vincenzo L. Malavasi and Giuseppe BorianiRed blood cell distribution width (RDW) is an inexpensive marker of anisocytosis easily available in the standard complete blood cell count. Besides its traditional use in the differential diagnosis of anemias, RDW values reflect abnormalities in erythropoiesis and red blood cell metabolism related to aging, sex, ethnicity, systemic inflammatory state, and oxidative stress. Thus, higher RDW values are common findings in several acut Read More
-
-
-
Association of Viruses in the Development of Cardiovascular Diseases
Cardiovascular diseases (CVD), primarily inflammatory cardiomyopathy, are characterized by the infiltration of inflammatory cells into the myocardium. It has a relatively high risk of deteriorating heart function and has heterogeneous etiologies. Inflammatory cardiomyopathy is mainly mediated by viral infections but can also be mediated by protozoa, fungal or bacterial infections. Besides that, there are a wide variety o Read More
-
-
-
The Pathogenic Subpopulation of Th17 Cells in Obesity
Obesity is a metabolic disease characterized by a chronic subclinical inflammatory response associated with an imbalance/dysregulation of cellular homeostasis in response to excessive nutrient intake and accumulation. CD4+ T-lymphocytes form different populations, Th1, Th2, Th9, Th17, Th22, and Treg cells, which have phenotypic and functional differences. Despite the active study of Th17 cells in severe disorders, their r Read More
-
-
-
Gut-Brain-Microbiota Axis and Hypertension: A Literature Review
Authors: Young N. Kwon and Yong-Jae KimThe gut and brain are linked via various bidirectional pathways, and they communicate withand affect each other. The interaction between the gut-brain axis and the gut microbiota has attracted much attention in the development of hypertension. In this review, we have discussed the gut-brain-microbiota axis and its association with gut dysbiosis in terms of regulation of blood pressure using the autonomic nervous system, imm Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
- Issue 46
- Issue 45
- Issue 44
- Issue 43
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 4
- Issue 7
- Issue 6
- Issue 5
- Issue 3
- Issue 2
- Issue 1
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
